Stemline Therapeutics (STML)

[zc182]

Seems to me like the deal isn't set in stone. Would be very cautious on this one. According to the recent price, best you can ask for is 4% to tie your money up for a long time with serious risk that the deal falls through.

Keep this as far away from my money as possible.

[TonyJoe1957]

Short squeeze in progress.

[TheFinalCD]

CONGRAT$ STML Stemline Therapeutics to be Acquired by Menarini Group in $677 Million Deal https://t.co/R9SlT7Jh2b

[biotech_researcher]

Filing: another 7% owner in Stemline:


https://ir.stemline.com/static-files/8d942d26-5aa7-45bb-8219-e9d65529641b

[biotech_researcher]

BlackRock discloses 7.4% stake in Stemline:


https://ir.stemline.com/sec-filings/sec-filing/sc-13ga/0000834237-20-006933

[biotech_researcher]

Eventide claims a 8.3% ownership


https://ir.stemline.com/static-files/e641d603-7d25-4c94-85fb-4088256a8bb1

[trustbutverifyit]

Added this one to my watch list. Looking promising with the Cantor Fitzgerald overweight rating and PT of $18.

[biotech_researcher]

Stemline Therapeutics: Post-ASH Update For This Leader In The CD123 Space $STML

https://seekingalpha.com/article/4312042

Excellent overview...

[biotech_researcher]

ASH clinical trial results

https://ir.stemline.com/news-releases/news-release-details/stemline-therapeutics-recaps-elzonris-clinical-data

[biotech_researcher]

Tagraxofusp has been a welcome new addition and a successful initial development step in the targeted treatment of BPDCN. In phase I/II clinical trial, major responses were observed in 90% of treatment naïve patients, with 72% of the responses observed as complete remissions.

[biotech_researcher]

Stemline’s three presentations at ASH in Orlando next week:


Details on the ASH presentations are as follows:

Myelofibrosis – Clinical (monotherapy); oral presentation
Title: Results from a Phase 1/2 Clinical Trial of Tagraxofusp (SL-401) in Patients with Intermediate, or High Risk, Relapsed/Refractory Myelofibrosis
Presenter: Naveen Pemmaraju, MD; MD Anderson Cancer Center
Abstract: 558
Session: 634. Myeloproliferative Syndromes: Clinical: Emerging and Novel Targeted Therapies
Date/Time: Monday, December 9, 2019 8:15 AM ET
Location: Orange County Convention Center, W304EFGH

Multiple Myeloma – Clinical (combination therapy); poster presentation
Title: Results from Phase 1/2 Trial of Tagraxofusp in Combination with Pomalidomide and Dexamethasone in Relapsed or Refractory Multiple Myeloma
Presenter: Paul G. Richardson, M.D.; Dana-Farber Cancer Institute
Abstract: 3145
Session: 653. Myeloma: Therapy, excluding Transplantation: Poster II
Date/Time: Sunday, December 8, 2019 6:00 PM–8:00 PM ET
Location: Orange County Convention Center, Hall B

Myeloproliferative Neoplasms – Preclinical (combination therapy); poster presentation
Title: Evaluation of Tagraxofusp (SL-401) Alone and in Combination with Ruxolitinib for the Treatment of Myeloproliferative Neoplasms
Presenter: Aishwarya Krishnan, MD; Memorial Sloan Kettering Cancer Center
Abstract: 2967
Session: 635. Myeloproliferative Syndromes: Basic Science: Poster II
Date/Time: Sunday, December 8, 2019 6:00 PM–8:00 PM ET
Location: Orange County Convention Center, Hall B

[whytestocks]

News: $STML Stemline Therapeutics to Present at Piper Jaffray's 31st Annual Healthcare Conference

NEW YORK, Nov. 29, 2019 (GLOBE NEWSWIRE) -- Stemline Therapeutics, Inc. (Nasdaq: STML), a commercial-stage biopharmaceutical company focused on the development and commercialization of novel oncology therapeutics, today announced that Stemline management will present at Piper Jaffray’...

Find out more STML - Stemline Therapeutics to Present at Piper Jaffray's 31st Annual Healthcare Conference

[biotech_researcher]

Stem line reports Q3 results

-$13 million in sales


https://ir.stemline.com/news-releases/news-release-details/stemline-therapeutics-reports-third-quarter-2019-financial

[biotech_researcher]

STML- Stemline Therapeutics Announces Three ELZONRIS Presentations, Including an Oral Presentation in Myelofibrosis, at Upcoming ASH Meeting


https://ir.stemline.com/news-releases/news-release-details/stemline-therapeutics-announces-three-elzonris-presentations

[biotech_researcher]

https://ir.stemline.com/news-releases/news-release-details/stemline-therapeutics-announces-elzonrisr-clinical-data-selected

[biotech_researcher]

SL-801 Poster from 2019 ESMO

http://stemline.com/wp-content/uploads/2019/09/SL-801-poster-ESMO-2019-09-28-19-.pdf

[whytestocks]

News: $STML Stemline Therapeutics Announces Felezonexor (SL-801) Clinical Data to be Featured at Upcoming ESMO 2019 Congress

NEW YORK, Sept. 27, 2019 (GLOBE NEWSWIRE) -- Stemline Therapeutics, Inc. (Nasdaq: STML), a commercial-stage biopharmaceutical company focused on the development and commercialization of novel oncology therapeutics, today announced that clinical data on felezonexor (SL-801) has been selected...

Read the whole news STML - Stemline Therapeutics Announces Felezonexor (SL-801) Clinical Data to be Featured at Upcoming ESMO 2019 Congress

[whytestocks]

News: $STML Stemline Therapeutics to Present at the Ladenburg Thalmann 2019 Healthcare Conference

NEW YORK, Sept. 18, 2019 (GLOBE NEWSWIRE) -- Stemline Therapeutics, Inc. (Nasdaq: STML), a commercial-stage biopharmaceutical company focused on the development and commercialization of novel oncology therapeutics, today announced that Ivan Bergstein, M.D., Stemline’s CEO, will prese...

Find out more STML - Stemline Therapeutics to Present at the Ladenburg Thalmann 2019 Healthcare Conference

[biotech_researcher]

Ivan’s presentation at the biotech conference in NY was very informative. Deep pipeline with at least two readouts in the remainder of this year. EU approval early next year. Q3 sales in the US may set the stage for a great 12 months..

[biotech_researcher]

Great granular presentation on Stemline’s pipeline..

http://wsw.com/webcast/wedbush35/stml/index.aspx

[biotech_researcher]

STML- • Stemline Therapeutics (NASDAQ:STML) prices its public offering of 5M common shares at $15.25 per share. Underwriters over-allotment is an additional 750K shares. Closing date is August 13.
• Yesterday's close was $16.50.
• Shares down 4% premarket on light volume.

[biotech_researcher]

STML up 18% on twice average volume. My top pick in 2019

[whytestocks]

News: $STML Stemline Therapeutics Announces that CMS Grants New Technology Add-on Payment (NTAP) to ELZONRIS®

NEW YORK, Aug. 06, 2019 (GLOBE NEWSWIRE) -- Stemline Therapeutics, Inc. (Nasdaq: STML), a commercial-stage biopharmaceutical company focused on the development and commercialization of novel oncology therapeutics, today announced that the Centers for Medicare & Medicaid Services (CMS) g...

Find out more Stemline Therapeutics Announces that CMS Grants New Technology Add-on Payment (NTAP) to ELZONRIS®

[ClayTrader]

* * $STML Video Chart 08-02-2019 * *

Link to Video - click here to watch the technical chart video

[biotech_researcher]

Webbush upgrades and raises target to $20 due in part to the unexpected sales beat..

https://thefly.com/landingPageNews.php?id=2944465&headline=STML-Wedbush-upgrades-Stemline--to-Outperform-after-Elzonris-sales-beat

[biotech_researcher]

Stemline Theraputics STML

Stemline Therapeutics (NASDAQ:STML): Q2 GAAP EPS of -$0.42 beats by $0.14.
Revenue of $13M beats by $6.5M.

https://seekingalpha.com/pr/17591900-stemline-therapeutics-reports-second-quarter-2019-financial-results

[whytestocks]

News: $STML Stemline Therapeutics Reports Second Quarter 2019 Financial Results

Net revenue for ELZONRIS® was $13.0 million for the second quarter Conference call and live webcast scheduled for today at 8:00 AM ET NEW YORK, Aug. 02, 2019 (GLOBE NEWSWIRE) -- Stemline Therapeutics, Inc. (Nasdaq: STML), a commercial-stage biopharmaceutical company focused on...

In case you are interested Stemline Therapeutics Reports Second Quarter 2019 Financial Results

[biotech_researcher]

<div style="width:700px;height:420px;"><iframe src="https://riskvar.com/wp-admin/admin-ajax.php?action=loadchart&id=557"; frameborder="0" scrolling="no" width="700" height="420" title="RiskVar.com"></iframe><div style="font-family: Arial, sans-serif;text-align: center;position: relative;font-size:10px;max-width:600px;">Powered by RiskVar.com<a style="font-size:10px;color:#428bca;text-decoration:none;" href="https://riskvar.com"; target="_blank">Financial Risk Management</a></div></div>

[biotech_researcher]

STML: Stemline Therapeutics highlights recent clinical and regulatory developments and details upcoming milestones (14.32 -0.16)
Stemline continues to build out a European commercial infrastructure in advance of potential approval by the EMA. A scientific advisory group meeting is planned for September, and the ELZONRIS marketing authorization application (MAA) review will proceed on a standard timeline. Co expects an opinion by the Committee for Medicinal Products for Human Use later this year. If successful, Stemline is targeting a commercial launch in Europe in 1Q20.
In an ongoing market expansion effort, corporate and investigator-sponsored clinical trials with ELZONRIS in additional indications are ongoing in myelofibrosis (MF) and acute myeloid leukemia (AML) and others are planned to roll out later this year and next.

[biotech_researcher]

https://twitter.com/caesarbiotech/status/773124984914976768?s=21

[biotech_researcher]

https://www.mdanderson.org/publications/cancerwise/new-blastic-plasmacytoid-dendritic-cell-neoplasm--bpdcn--treatment-shows-promise-for-patients.h00-159303834.html#.XQ-HsiXsoW4.twitter

[biotech_researcher]

Stemline Therapeutics Announces Presentation of ELZONRIS (tagraxofusp) Preclinical Data in Systemic Sclerosis, an Autoimmune Disorder, at EULAR Congress

https://forextv.com/top-news/stemline-therapeutics-announces-presentation-of-elzonris-tagraxofusp-preclinical-data-in-systemic-sclerosis-an-autoimmune-disorder-at-eular-congress/

[biotech_researcher]

This is my pick for one of the best over the next twelve months:

https://finance.yahoo.com/news/stemline-therapeutics-announces-presentation-elzonris-113000225.html

Plus, EU approval for their CD123 compound (was approved by FDA in December 2018)

[biotech_researcher]

Three upcoming poster presentations at EHA:

http://www.globenewswire.com/news-release/2019/05/20/1827659/0/en/Stemline-Therapeutics-Announces-ELZONRIS-Clinical-Data-Selected-for-Presentation-at-Upcoming-EHA-Annual-Congress.html

[biotech_researcher]

STML reports Q1 2019 results. First quarter since FDA approval. Revenue was double the estimate.

https://finance.yahoo.com/news/stemline-therapeutics-reports-first-quarter-103000360.html

[biotech_researcher]

STML has never looked back through all this market turmoil through 2019. Q1 results are tomorrow at 8 AM.

[biotech_researcher]

Stemline Therapeutics Announces New England Journal of Medicine Publication of ELZONRIS (tagraxofusp) Pivotal Study Results

https://finance.yahoo.com/news/stemline-therapeutics-announces-england-journal-110000838.html

[biotech_researcher]

Ripping......

[biotech_researcher]

Approved by FDA for BPDCN, rare blood cancer (500-1000 pts annually) with CD113 mutation. No other treatment available. STML has a Very robust pipeline.

$STML Upcoming Tagraxofusp in BPDCN pivotal clinical trial publication in NEJM April 25 edition. No real surprises. Of 29 patients not previously treated, 90% ORR, 13 bridged to transplant, and 52% alive at 2 years. In 13 prev tx'd, ORR=67%, and median OS = 8.5 mos. CLS in 1/44

[biotech_researcher]

CD123 makes a great target for many indications..

[Lazarus]

Sold last week at $9.47 and then bought back in the other day at $9.33. Not liking that they haven't announced the pricing on the shares they're selling so its looking iffy to me here. I'm out at $9.68 and will wait for more details on the offering.

Whenever a stock gets FDA approval and it can't move --- you know something isn't right.

[biotech_researcher]

Unmet medical need. Should strengthen....

[Lazarus]

Now that the stock is in the toilet and the company finally gets an FDA approval its CRICKETS on the board. Too funny. I'm in at $8.07

U.S. FDA approves Stemline Therapeutics' rare blood disease treatment

Dec 21 (Reuters) - The U.S. Food and Drug Administration on Friday approved Stemline Therapeutics Inc's Elzonris for the treatment of a rare blood disease in adults and children aged two years and above.

This is the first approved treatment for the condition, blastic plasmacytoid dendritic cell neoplasm (BPDCN), Richard Pazdur, director of the FDA's Oncology Center of Excellence, said.

"The standard of care has been intensive chemotherapy, followed by bone marrow transplantation. Many patients with BPDCN are unable to tolerate this intensive therapy, so there is an urgent need for alternative treatment options."

BPDCN is an aggressive and rare disease of the bone marrow and blood that can affect multiple organs, including the lymph nodes and the skin, the FDA said.

The condition is more common in men than women, and in patients who are 60 years and above.

The labeling for Elzonris contains a boxed warning, FDA's harshest, flagging increased risk of capillary leak syndrome, which may be life-threatening or fatal to patients in treatment.

Stemline Therapeutics shares fell as much as 7.8 percent to $8 in early trading.

[cashcow3]

http://petroglobalnews24.com/2017-03-22-ladenburg-thalmann-financial-services-analysts-give-stemline-therapeutics-inc-stml-a-41-00-price-target/

[cashcow3]

Perceptive Advisors LLC bought a new position in shares of Stemline Therapeutics during the fourth quarter worth $115,000. Bogle Investment Management L P DE bought a new position in shares of Stemline Therapeutics during the fourth quarter worth $1,015,000. Renaissance Technologies LLC raised its position in shares of Stemline Therapeutics by 7.9% in the fourth quarter. Renaissance Technologies LLC now owns 65,500 shares of the biopharmaceutical company’s stock worth $701,000 after buying an additional 4,800 shares during the period. Finally, J. Goldman & Co LP bought a new position in shares of Stemline Therapeutics during the fourth quarter worth $2,139,000. Institutional investors own 37.76% of the company’s stock.

[cashcow3]

Stemline Therapeutics Inc (NASDAQ:STML) has been given a $41.00 price objective by analysts at Ladenburg Thalmann Financial Services in a report issued on Monday. The brokerage presently has a “buy” rating on the biopharmaceutical company’s stock. Ladenburg Thalmann Financial Services’ target price indicates a potential upside of 327.08% from the company’s current price.

[cashcow3]

http://www.globenewswire.com/news-release/2017/03/23/943431/0/en/Stemline-Therapeutics-Announces-Completion-of-Enrollment-in-Stage-3-of-the-SL-401-Pivotal-Trial-in-BPDCN.html

[cashcow3]

HUGE NEWS

Completes Stage 3 Enrollment
Stemline has completed enrollment of the Stage 3 cohort of the SL-401 pivotal trial in BPDCN. Stage 3 enrolled 13 first-line BPDCN patients; statistical analysis will be based on evaluable first-line patients. The registration pathway was previously agreed upon with the U.S. Food and Drug Administration (FDA). Depending on the data from the trial, Stemline plans to use the results generated to support the potential filing of a Biologics License Application (BLA) for full approval in first-line BPDCN, and is targeting possible BLA filing in the second half of this year.

[trendmkr]

Stemline Therapeutics Inc (NASDAQ:STML): What’s The Other Side Of The Story? https://marketexclusive.com/stemline-therapeutics-inc-nasdaqstml-whats-side-story/71032/?icd1

[guchu]

Stemline says patient died during Phase 2 BPDCN trial

On January 18, the company received a report that a patient death had occurred. The patient had developed capillary leak syndrome, a known, sometimes fatal, and well-documented side effect of SL-401

http://thefly.com/landingPageNews.php?id=2499112&headline=STML-Stemline-says-patient-died-during-Phase--BPDCN-trial